{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:29:34Z","timestamp":1745386174140},"reference-count":21,"publisher":"Media Sphere Publishing Group","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2020]]},"DOI":"10.17116\/jnevro2020120041123","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:56:45Z","timestamp":1591196205000},"page":"123","source":"Crossref","is-referenced-by-count":3,"title":["Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology"],"prefix":"10.17116","volume":"120","author":[{"given":"M.M.","family":"Tanashyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.I.","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Raskurazhev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro2020120041123-1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659"},{"key":"key-10.17116\/jnevro2020120041123-2","unstructured":"Suslina ZA, Tanashyan MM, Ionova VG. Ishemicheskii insul\u2019t: krov\u2019, sosudistaya stenka, antitromboticheskaya terapiya. M.: Meditsinskaya kniga; 2005. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120041123-3","unstructured":"Tanashyan MM. Gemostaz, gemoreologiya i atrombogennaya aktivnost\u2019 sosudistoj stenki v angionevrologii. Annaly klinicheskoj i eksperimental\u2019noj nevrologii. 2007;2(1):29-33. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120041123-4","unstructured":"Tanashyan MM, Lagoda OV, Gulevskaya TS, Maksyutkina LN, Raskurazhev AA. Progressing cerebral atherosclerosis: clinical, biochemical and morphological aspects. Annaly klinicheskoi i eksperimental\u2019noi nevrologii. 2013;7(4):4-9. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120041123-5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2012.12.013"},{"key":"key-10.17116\/jnevro2020120041123-6","doi-asserted-by":"crossref","unstructured":"International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569-1581","DOI":"10.1016\/S0140-6736(97)04011-7"},{"key":"key-10.17116\/jnevro2020120041123-7","doi-asserted-by":"crossref","unstructured":"CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641-1649","DOI":"10.1016\/S0140-6736(97)04010-5"},{"key":"key-10.17116\/jnevro2020120041123-8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"key-10.17116\/jnevro2020120041123-9","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024"},{"key":"key-10.17116\/jnevro2020120041123-10","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000158"},{"key":"key-10.17116\/jnevro2020120041123-11","doi-asserted-by":"crossref","unstructured":"CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"key-10.17116\/jnevro2020120041123-12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70361-8"},{"key":"key-10.17116\/jnevro2020120041123-13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000163561.90680.1C"},{"key":"key-10.17116\/jnevro2020120041123-14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70060-0"},{"key":"key-10.17116\/jnevro2020120041123-15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70250-8"},{"key":"key-10.17116\/jnevro2020120041123-16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"key-10.17116\/jnevro2020120041123-17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32849-0"},{"key":"key-10.17116\/jnevro2020120041123-18","doi-asserted-by":"crossref","unstructured":"Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 2006;12 (2):251-258","DOI":"10.2174\/138161206775193064"},{"key":"key-10.17116\/jnevro2020120041123-19","unstructured":"Tanashyan MM, Domashenko MA, Raskurazhev AA. Aspirin resistance: clinical and molecular genetic evaluation techniques. Annaly klinicheskoj i eksperimental\u2019noj nevrologii. 2016;1(10):41-46. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120041123-20","unstructured":"Tanashyan MM, Domashenko MA. Primenenie Kurantila pri hronicheskih cerebrovaskulyarnyh zabolevaniyah. Nervnye bolezni. 2005;3:8-11. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120041123-21","doi-asserted-by":"crossref","unstructured":"Tanashyan MM, Kuznetsova PI, Raskurazhev AA. Rational Pharmacotherapy of Cerebrovascular Disorders Caused by Myeloproliferative Diseases. Nervnye bolezni. 2016;3:3-6. (In Russ.)","DOI":"10.1159\/000448597"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:59:10Z","timestamp":1591196350000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2020\/4\/downloads\/ru\/1199772982020041123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"alternative-id":["10.17116\/jnevro2020120041123"],"URL":"https:\/\/doi.org\/10.17116\/jnevro2020120041123","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}